• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

动态[F]FDG PET/CT 研究立体定向体部放疗对患者区域性代谢肝功能的影响。

Effect of stereotactic body radiotherapy on regional metabolic liver function investigated in patients by dynamic [F]FDGal PET/CT.

机构信息

Departement of Nuclear Medicine & PET, Aarhus University Hospital, Aarhus N, Denmark.

Departement of Hepatology & Gastroenterology, Aarhus University Hospital, Palle Juul-Jensens Boulevard 99, C116, 8200, Aarhus N, Denmark.

出版信息

Radiat Oncol. 2021 Oct 1;16(1):192. doi: 10.1186/s13014-021-01909-z.

DOI:10.1186/s13014-021-01909-z
PMID:34598730
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8485519/
Abstract

PURPOSE

Stereotactic body radiotherapy (SBRT) is increasingly used for treatment of liver tumors but the effect on metabolic liver function in surrounding tissue is largely unknown. Using 2-deoxy-2-[F]fluoro-D-galactose ([F]FDGal) positron emission tomography (PET)/computed tomography (CT), we aimed to determine a dose-response relationship between radiation dose and metabolic liver function as well as recovery.

PROCEDURES

One male subject with intrahepatic cholangiocarcinoma and five subjects (1 female, 4 male) with liver metastases from colorectal cancer (mCRC) underwent [F]FDGal PET/CT before SBRT and after 1 and 3 months. The dose response was calculated using the data after 1 month and the relative recovery was evaluated after 3 months. All patients had normal liver function at time of inclusion.

RESULTS

A linear dose-response relationship for the individual liver voxel dose was seen until approximately 30 Gy. By fitting a polynomial curve to data, a mean TD of 18 Gy was determined with a 95% CI from 12 to 26 Gy. After 3 months, a substantial recovery was observed except in tissue receiving more than 25 Gy.

CONCLUSIONS

[F]FDGal PET/CT makes it possible to determine a dose-response relationship between radiation dose and metabolic liver function, here with a TD of 18 Gy (95% CI 12-26 Gy). Moreover, the method makes it possible to estimate metabolic recovery in liver tissue.

摘要

目的

立体定向体放射治疗（SBRT）越来越多地用于治疗肝脏肿瘤，但周围组织代谢肝功能的影响在很大程度上尚不清楚。本研究采用 2-脱氧-2-[F]氟-D-半乳糖([F]FDGal)正电子发射断层扫描（PET）/计算机断层扫描（CT），旨在确定辐射剂量与代谢肝功能以及恢复之间的剂量反应关系。

方法

1 名男性肝内胆管细胞癌患者和 5 名（1 名女性，4 名男性）结直肠癌（mCRC）肝转移患者在 SBRT 前、治疗后 1 个月和 3 个月进行[F]FDGal PET/CT 检查。使用 1 个月后的数据计算剂量反应，并用 3 个月后的相对恢复来评估。所有患者在纳入时肝功能正常。

结果

个体肝像素剂量的线性剂量反应关系可见至约 30Gy。通过对数据拟合多项式曲线，得出平均 TD 为 18Gy，95%CI 为 12-26Gy。3 个月后，除了接受超过 25Gy 剂量的组织外，观察到明显的恢复。

结论

[F]FDGal PET/CT 可用于确定辐射剂量与代谢肝功能之间的剂量反应关系，此处的 TD 为 18Gy（95%CI 12-26Gy）。此外，该方法可用于估计肝脏组织的代谢恢复。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/afe5/8485519/9fb1409ab655/13014_2021_1909_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/afe5/8485519/49d7435eb0f1/13014_2021_1909_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/afe5/8485519/12d5ef1d1a73/13014_2021_1909_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/afe5/8485519/9fb1409ab655/13014_2021_1909_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/afe5/8485519/49d7435eb0f1/13014_2021_1909_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/afe5/8485519/12d5ef1d1a73/13014_2021_1909_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/afe5/8485519/9fb1409ab655/13014_2021_1909_Fig3_HTML.jpg

相似文献

1
Effect of stereotactic body radiotherapy on regional metabolic liver function investigated in patients by dynamic [F]FDGal PET/CT.动态[F]FDG PET/CT 研究立体定向体部放疗对患者区域性代谢肝功能的影响。
Radiat Oncol. 2021 Oct 1;16(1):192. doi: 10.1186/s13014-021-01909-z.
2
A phase I study on stereotactic body radiotherapy of liver metastases based on functional treatment planning using positron emission tomography with 2-[F]fluoro-2-deoxy-d-galactose.一项基于使用2-[F]氟-2-脱氧-D-半乳糖正电子发射断层扫描进行功能治疗计划的肝转移瘤立体定向体部放射治疗的I期研究。
Acta Oncol. 2017 Nov;56(11):1614-1620. doi: 10.1080/0284186X.2017.1366051. Epub 2017 Aug 29.
3
Hepatic galactose metabolism quantified in humans using 2-18F-fluoro-2-deoxy-D-galactose PET/CT.使用 2-[18F]氟-2-脱氧-D-半乳糖 PET/CT 对人体肝脏半乳糖代谢进行定量研究。
J Nucl Med. 2011 Oct;52(10):1566-72. doi: 10.2967/jnumed.111.092924. Epub 2011 Aug 29.
4
The lumped constant for the galactose analog 2-18F-fluoro-2-deoxy-D-galactose is increased in patients with parenchymal liver disease.在实质肝疾病患者中，半乳糖类似物 2-18F-氟-2-脱氧-D-半乳糖的团集常数增加。
J Nucl Med. 2014 Apr;55(4):590-4. doi: 10.2967/jnumed.113.125559. Epub 2014 Mar 3.
5
Regional metabolic liver function measured in patients with cirrhosis by 2-[¹⁸F]fluoro-2-deoxy-D-galactose PET/CT.肝硬化患者通过 2-[¹⁸F]氟代-2-脱氧-D-半乳糖 PET/CT 测量的区域性代谢肝功能。
J Hepatol. 2013 Jun;58(6):1119-24. doi: 10.1016/j.jhep.2013.01.012. Epub 2013 Jan 20.
6
2-[(18)F]fluoro-2-deoxy-D-galactose PET/CT of hepatocellular carcinoma is not improved by co-administration of galactose.肝癌的2-[(18)F]氟-2-脱氧-D-半乳糖PET/CT检查在联合给予半乳糖时并无改善。
Nucl Med Biol. 2016 Sep;43(9):577-580. doi: 10.1016/j.nucmedbio.2016.06.002. Epub 2016 Jun 28.
7
The potential use of 2-[¹⁸F]fluoro-2-deoxy-D-galactose as a PET/CT tracer for detection of hepatocellular carcinoma.2-[¹⁸F]氟-2-脱氧-D-半乳糖作为 PET/CT 示踪剂用于肝细胞癌检测的潜在用途。
Eur J Nucl Med Mol Imaging. 2011 Sep;38(9):1723-31. doi: 10.1007/s00259-011-1831-z. Epub 2011 May 7.
8
[ F]-Fluoro-2-deoxy-D-galactose positron emission tomography/computed tomography as complementary imaging tool in patients with hepatocellular carcinoma.[F]-氟-2-脱氧-D-半乳糖正电子发射断层扫描/计算机断层扫描作为肝细胞癌患者的补充成像工具
Liver Int. 2020 Feb;40(2):447-455. doi: 10.1111/liv.14293. Epub 2019 Nov 25.
9
Determination of hepatic galactose elimination capacity using 2-[¹⁸F]fluoro-2-deoxy-D-galactose PET/CT: reproducibility of the method and metabolic heterogeneity in a normal pig liver model.使用2-[¹⁸F]氟-2-脱氧-D-半乳糖PET/CT测定肝脏半乳糖清除能力：该方法在正常猪肝模型中的可重复性及代谢异质性
Scand J Gastroenterol. 2011 Jan;46(1):98-103. doi: 10.3109/00365521.2010.510574. Epub 2010 Aug 9.
10
Fluorodeoxyglucose positron emission tomography response and normal tissue regeneration after stereotactic body radiotherapy to liver metastases.氟脱氧葡萄糖正电子发射断层扫描反应与立体定向体部放射治疗肝转移瘤后正常组织再生。
Int J Radiat Oncol Biol Phys. 2012 Aug 1;83(5):e613-8. doi: 10.1016/j.ijrobp.2012.02.008. Epub 2012 Apr 10.

引用本文的文献

1
Radiomics Beyond Radiology: Literature Review on Prediction of Future Liver Remnant Volume and Function Before Hepatic Surgery.放射组学超越放射学：肝脏手术前预测未来肝剩余体积和功能的文献综述
J Clin Med. 2025 Jul 28;14(15):5326. doi: 10.3390/jcm14155326.
2
Evaluation of the effect of locoregional treatment on metabolic liver function in hepatocellular carcinoma using F-FDGal PET/CT.使用F-FDGal PET/CT评估局部区域治疗对肝细胞癌代谢性肝功能的影响。
EJNMMI Res. 2025 Jul 16;15(1):88. doi: 10.1186/s13550-025-01285-9.
3
evaluation of liver function by multimodal imaging in an alcohol-induced liver injury model.

本文引用的文献

1
Radiation Dose-Volume Effects for Liver SBRT.肝 SBRT 的剂量-体积效应。
Int J Radiat Oncol Biol Phys. 2021 May 1;110(1):196-205. doi: 10.1016/j.ijrobp.2017.12.290. Epub 2018 Jan 6.
2
Metabolic liver function in humans measured by 2-F-fluoro-2-deoxy-D-galactose PET/CT-reproducibility and clinical potential.用2-F-氟-2-脱氧-D-半乳糖PET/CT测量人类代谢肝功能：再现性及临床潜力
EJNMMI Res. 2017 Aug 29;7(1):71. doi: 10.1186/s13550-017-0320-1.
3
A phase I study on stereotactic body radiotherapy of liver metastases based on functional treatment planning using positron emission tomography with 2-[F]fluoro-2-deoxy-d-galactose.
在酒精性肝损伤模型中通过多模态成像评估肝功能
Quant Imaging Med Surg. 2023 Oct 1;13(10):6434-6445. doi: 10.21037/qims-23-122. Epub 2023 Aug 10.
4
Fluorinated carbohydrates for F-positron emission tomography (PET).氟代碳水化合物用于正电子发射断层扫描（PET）。
Chem Soc Rev. 2023 Jun 6;52(11):3599-3626. doi: 10.1039/d3cs00037k.
一项基于使用2-[F]氟-2-脱氧-D-半乳糖正电子发射断层扫描进行功能治疗计划的肝转移瘤立体定向体部放射治疗的I期研究。
Acta Oncol. 2017 Nov;56(11):1614-1620. doi: 10.1080/0284186X.2017.1366051. Epub 2017 Aug 29.
4
Radiotherapy for Hepatocellular Carcinoma: New Indications and Directions for Future Study.肝细胞癌的放射治疗：新适应症及未来研究方向
J Natl Cancer Inst. 2016 Jul 4;108(9). doi: 10.1093/jnci/djw133. Print 2016 Sep.
5
Phase 1 Trial of Sorafenib and Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma.索拉非尼和立体定向体部放射治疗肝细胞癌的 1 期试验。
Int J Radiat Oncol Biol Phys. 2016 Mar 1;94(3):580-7. doi: 10.1016/j.ijrobp.2015.11.048. Epub 2015 Dec 17.
6
Survival and prognostic factors in 321 patients treated with stereotactic body radiotherapy for oligo-metastases.321 例寡转移患者行立体定向体部放疗的生存和预后因素分析。
Radiother Oncol. 2015 Feb;114(2):155-60. doi: 10.1016/j.radonc.2014.12.003. Epub 2015 Jan 9.
7
The lumped constant for the galactose analog 2-18F-fluoro-2-deoxy-D-galactose is increased in patients with parenchymal liver disease.在实质肝疾病患者中，半乳糖类似物 2-18F-氟-2-脱氧-D-半乳糖的团集常数增加。
J Nucl Med. 2014 Apr;55(4):590-4. doi: 10.2967/jnumed.113.125559. Epub 2014 Mar 3.
8
Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma.立体定向体部放疗治疗局部进展期肝细胞癌的序贯 I 期和 II 期临床试验。
J Clin Oncol. 2013 May 1;31(13):1631-9. doi: 10.1200/JCO.2012.44.1659. Epub 2013 Apr 1.
9
Regional metabolic liver function measured in patients with cirrhosis by 2-[¹⁸F]fluoro-2-deoxy-D-galactose PET/CT.肝硬化患者通过 2-[¹⁸F]氟代-2-脱氧-D-半乳糖 PET/CT 测量的区域性代谢肝功能。
J Hepatol. 2013 Jun;58(6):1119-24. doi: 10.1016/j.jhep.2013.01.012. Epub 2013 Jan 20.
10
Radiotherapy for liver metastases: a review of evidence.肝脏转移瘤放射治疗：证据回顾。
Int J Radiat Oncol Biol Phys. 2012 Mar 1;82(3):1047-57. doi: 10.1016/j.ijrobp.2011.07.020.